NCT07162532Not yet recruiting
Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia Patients
Impact of Clinico-hematological and Molecular Characteristics on Treatment Outcomes of Chronic Lymphocytic Leukemia Patients
Source: ClinicalTrials.gov · Last updated 9 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
the goal of this study is To describe the clinical, hematologic, and cytogenetic characteristics of CLL cases. The main questions it aims to answer are: 1. what is the impact of cytogenetics abnormalities \[e.g., IGHV mutation status, del(17p)\] on patients' treatment response? 2. what is th correlation between clinical and hematological characteristic with patients' outcome. All participants will be subjected to history taking , Physical examination. and Laboratory investigations (Complete blood picture Cytogenetic profiles: del(17p) molecular study :IGHV mutation status).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 11 Jul 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Aug 2026
- Lead sponsor
- Assiut University
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT07162532
What you commit to
- Study type: Observational
- Planned participants: 45
- From 1 Oct 2025 to the primary completion date, 1 Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Incomplete diagnostics (e.g. flowcytometry of cytogenetics)
- Lost to follow-up within 12 months of diagnosis.
- Refused to give informed consent
Who the study is looking for
- Age ≥ 18 years newly diagnosed with CLL.
- Adequate diagnostics (flowcytometry and cytogenetics) and follow-up data (at least 1 year).
- Patients giving informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.